Bio Green Med Solution, Inc.
Close on Oct 19, 2026
- Market cap
- $5.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | $336.00K | $-0.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $778.00K | $-0.04 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | After market close | $666.00K | $-2.21 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | $-0.98 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 2, 2025 | After market close | – | $-0.33 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $10.00K | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | $4.00K | $-0.72 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | – | – |
Press releases
Announcements Bio Green Med Solution filed with the SEC
GREEN MED SOLUTION Reports SECOND quarter financial results and provides business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Green Med Solution, INC. Announces Business Combination Agreement to acquire Future NRG Sdn. Bhd.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GREEN MED SOLUTION Reports FIRST quarter financial results and provides business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
GREEN MED SOLUTION Reports FOURTH quarter AND FULL YEAR 2025 financial results and provides business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
GREEN MED SOLUTION Reports THIRD quarter financial results and provides business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
Acquisition or disposition completed · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Fitters Unaudited Balance Sheet as of
Acquisition or disposition completed · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
CONDENSED PRO FORMA COMBINED BALANCE SHEET AS OF JUNE 30, 2025
Acquisition or disposition completed · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Pharmaceuticals Reports SECOND quarter financial results and provides business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequiremenT
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports FIRST quarter financial results and provides business update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, INC. Announces EXECUTION OF Share Exchange Agreement to Make Fitters Sdn. Bhd. its Wholly-owned Subsidiary to Accelerate
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
financial results and provides business update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CYCLACEL PHARMACEUTICALS ANNOUNCES $1 MILLION PRIVATE
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Pharmaceuticals ANNOUNCES CLOSING OF EXERCISE OF WARRANTS FOR $2.1 MILLION GROSS PROCEEDS
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports THIRD quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports SECOND quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports first quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals ANNOUNCES $8.0 MILLION PRIVATE PLACEMENT
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals ANNOUNCES CLOSING OF $8.0 MILLION PRIVATE PLACEMENT
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Pharmaceuticals Reports fourth quarter and full year 2023 financial results and provides business update
Results of operations · EX-99.1 to Form 8-K
Cyclacel Pharmaceuticals, Inc. (CYCC) BIOTECH SHOWCASE JANUARY 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports THIRD quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports SECOND quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports first quarter financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports fourth quarter and full year 2022 financial results and provides business update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports THIRD quarter 2022 financial results and provides business update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports SECOND quarter 2022 financial results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports first quarter 2022 financial results and provides business update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports THIRD Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K